Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 19

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 19
---
are a component of the total nanoparticle concentration but exosome levels over time were not specifically determined.

Research and Development Costs

A substantial portion of our operating
budget is used for research and development activities. The cost of research and development, all of which has been charged to operations,
amounted to approximately $2,212,000 and $2,520,000 in the fiscal years ended March 31, 2025 and 2024, respectively. For the three-month
periods ended June 30, 2025 and 2024, research as development expenses were $524,368 and $414,658, respectively.

Recent Developments

On June 25, 2025, the Company received noticefrom Nasdaq stating the Company has regained compliance with Listing Rule 5550(a)(2),
and that the matter is now closed.

Reverse Split – Following the approval of a reverse stock split at a Special Meeting of Stockholders on May 13, 2025, our Board of Directors approved a 1-for-8 reverse stock split of our outstanding shares of Common Stock, effective as of the close of business on June 6, 2025 with an effective trading date of June 9, 2025. Accordingly, each eight shares of outstanding common stock held by stockholders were combined into one share of common stock. Our authorized common stock remained at 60,000,000 shares following the stock split. We issued an additional 77 shares as a result of rounding up fractional shares related to the reverse stock split.

On June 2, 2025 a second patient was treated with the Hemopurifier at GenesisCare North Shore Hospital in Sydney, Australia.
The patient was treated with the Aethlon Hemopurifier for 4 hours in a single day and tolerated the procedure without complications. The
patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

| 7 |

Intellectual Property

We currently own or have license
rights to a number of U.S. and foreign patents and patent applications and endeavor to continually improve our intellectual property position.
We consider the protection of our technology, whether owned or licensed, to the exclusion of use by others, to be vital to our business.
While we intend to focus primarily on patented or patentable technology, we also rely on trade secrets, unpatented property, know-how,
regulatory exclusivity, patent extensions and continuing technological innovation to develop our competitive position. We also own certain